Intervention Protocol

You have free access to this content

Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors

  1. Marc Arbyn1,*,
  2. Andrew Bryant2,
  3. Pierre PL Martin-Hirsch3,
  4. Lan Xu1,
  5. Cindy Simoens4,
  6. Lauri Markowitz5

Editorial Group: Cochrane Gynaecological Cancer Group

Published Online: 30 DEC 2013

Assessed as up-to-date: 3 MAR 2011

DOI: 10.1002/14651858.CD009069.pub2


How to Cite

Arbyn M, Bryant A, Martin-Hirsch PPL, Xu L, Simoens C, Markowitz L. Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors (Protocol). Cochrane Database of Systematic Reviews 2013, Issue 12. Art. No.: CD009069. DOI: 10.1002/14651858.CD009069.pub2.

Author Information

  1. 1

    Scientific Institute of Public Health, Unit of Cancer Epidemiology, Brussels, Belgium

  2. 2

    Newcastle University, Institute of Health and Society, Newcastle upon Tyne, UK

  3. 3

    Royal Preston Hospital, Lancashire Teaching Hospital NHS Trust, Gynaecological Oncology Unit, Preston, Lancashire, UK

  4. 4

    University of Antwerp, Laboratory of Cell Biology and Histology, Antwerp, Belgium

  5. 5

    Centers for Disease Control and Prevention, ESB/DSTDP/NCHHSTP, Atlanta, GA, USA

*Marc Arbyn, Unit of Cancer Epidemiology, Scientific Institute of Public Health, Juliette Wytsmanstreet 14, Brussels, B-1050, Belgium. Marc.Arbyn@wiv-isp.be.

Publication History

  1. Publication Status: Edited (no change to conclusions), comment added to review
  2. Published Online: 30 DEC 2013

SEARCH

 

Abstract

  1. Top of page
  2. Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows:

To evaluate the immunogenicity, clinical efficacy, and safety of prophylactic HPV vaccines in females. The assessment of clinical efficacy will address protection against HPV infection (for homologous and heterologous HPV types), against re-infection, against cervical cancer and its precursors (high-grade CIN (grade 2 or grade 3), adenocarcinoma in situ) in women previously not exposed to HPV infection (negative at enrolment for both HPV DNA and antibodies against the vaccine HPV types). We will assess clinical effectiveness by evaluating outcomes in all women, irrespective of the HPV DNA or serology status at enrolment. Evaluation by fine age and time since sexual debut categories is also planned.